To see all protocols that comply with the WHO Essential Medicine List 

Clinical safety note
There are physical and operational differences between the different types of CADD® pumps. Incorrect programming can lead to over-infusion of medication and has the potential to cause serious injury and death. See the TGA Alert misidentification of a CADD® Legacy Plus Pump leading to over-infusion and ISMP safety alert regarding the rapid infusion of high dose fluorouracil.

Only health care professionals who have attained competency as per institutional guidelines in ambulatory infusion pump management and related competencies, e.g. safe administration, handling and waste management of cytotoxics, and central venous access device care, should perform these procedures.

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

02 Apr 2020